zacks.com
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Krystal Biotech, Inc.KRYSNASDAQ
Loading
Latest News
Loading news...
fool.com
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech position increased by $50.33 million, reflecting both trading and price movement effects.
zacks.com
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
defenseworld.net
Krystal Biotech (NASDAQ:KRYS) Shares Gap Up Following Better-Than-Expected Earnings
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) shares gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $276.45, but opened at $289.00. Krystal Biotech shares last traded at $285.45, with a volume of 212,409 shares. The company reported $1.70 earnings per
seekingalpha.com
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
seekingalpha.com
Krystal: Profitable Growth And The Expanding Reach Of HSV-1 Technology
Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajectory, high gross margins (94%), and disciplined R&D and SG&A spending. Phase 1 KB407 data in cystic fibrosis confirms molecular proof-of-concept, with a $2B+ opportunity targeting modulator-ineligible and suboptimal responder patients.
globenewswire.com
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S.
fool.com
Got $300? 2 Biotech Stocks to Buy and Hold Forever
Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.
defenseworld.net
Cookson Peirce & Co. Inc. Takes Position in Krystal Biotech, Inc. $KRYS
Cookson Peirce and Co. Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ: KRYS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,654 shares of the company's stock, valued at approximately $998,000. A number of other institutional investors have also added
defenseworld.net
Alps Advisors Inc. Decreases Stock Holdings in Krystal Biotech, Inc. $KRYS
Alps Advisors Inc. cut its stake in Krystal Biotech, Inc. (NASDAQ: KRYS) by 23.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,367 shares of the company's stock after selling 4,095 shares during the period. Alps Advisors Inc.'s
seekingalpha.com
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update
Krystal Biotech maintains a 'Strong Buy' rating, driven by robust VYJUVEK sales and significant pipeline progress. Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated patients. A single registrational trial of KB707 plus chemotherapy versus chemotherapy alone may support regulatory filing, with interim analysis expected in H2 2026.
globenewswire.com
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.
defenseworld.net
Principal Financial Group Inc. Boosts Stock Position in Krystal Biotech, Inc. $KRYS
Principal Financial Group Inc. raised its position in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) by 1.4% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 142,843 shares of the company's stock after buying an additional 1,960 shares during the quarter. Principal Financial
zacks.com
5 Stocks With Recent Price to Strengthen Your Portfolio
RFIL, BWMX, FET, KRYS and MAMA are five stocks showing sharp recent price strength as markets start 2026 strong.
zacks.com
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
Krystal Biotech (KRYS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
zacks.com
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com
Krystal Biotech: Beyond VYJUVEK Commercialization
Krystal Biotech is upgraded to Strong Buy, driven by Vyjuvek's commercial success and a robust catalyst-rich pipeline. KRYS boasts 96% gross margins, nearly $1B in cash, and a platform poised to deliver four rare disease drugs by 2030. Recent positive Phase 1 data for KB407 in cystic fibrosis derisks inhaled delivery, enhancing confidence in upcoming AATD and NSCLC programs.
zacks.com
5 Stocks With Recent Price Strength to Maximize Your Gains
ISSC, AUGO, OWLT, KRYS and IDN are among a select group of stocks showing strong recent price momentum.
zacks.com
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives
On a preliminary unaudited basis, Krystal Biotech expects revenues of $388-$389M in 2025. The company ended the year with $955M cash, and outlined 2026 plans as its pipeline advances.
seekingalpha.com
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript